Genmab A/S
DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES
Last updated:
Abstract:
Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.
Status:
Application
Type:
Utility
Filling date:
10 Dec 2021
Issue date:
25 Aug 2022